Suketu Upadhyay - Zimmer Biomet Ex CFO

ZIM Stock  EUR 101.45  0.10  0.1%   

Insider

Suketu Upadhyay is Ex CFO of Zimmer Biomet Holdings
Age 54
Phone574 267 6131
Webhttps://www.zimmerbiomet.com

Suketu Upadhyay Latest Insider Activity

Tracking and analyzing the buying and selling activities of Suketu Upadhyay against Zimmer Biomet stock is an integral part of due diligence when investing in Zimmer Biomet. Suketu Upadhyay insider activity provides valuable insight into whether Zimmer Biomet is net buyers or sellers over its current business cycle. Note, Zimmer Biomet insiders must abide by specific rules, including filing SEC forms every time they buy or sell Zimmer Biomet'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Zimmer Biomet Management Efficiency

The company has return on total asset (ROA) of 0.0371 % which means that it generated a profit of $0.0371 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0236 %, meaning that it generated $0.0236 on every $100 dollars invested by stockholders. Zimmer Biomet's management efficiency ratios could be used to measure how well Zimmer Biomet manages its routine affairs as well as how well it operates its assets and liabilities.
Zimmer Biomet Holdings has accumulated 5.32 B in total debt with debt to equity ratio (D/E) of 74.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Zimmer Biomet Holdings has a current ratio of 1.17, suggesting that it may not have the ability to pay its financial obligations in time and when they become due. Debt can assist Zimmer Biomet until it has trouble settling it off, either with new capital or with free cash flow. So, Zimmer Biomet's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Zimmer Biomet Holdings sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Zimmer to invest in growth at high rates of return. When we think about Zimmer Biomet's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Pat HaggertyHollywood Bowl Group
N/A
AC DScRamsay Health Care
70
Andrew JonesRamsay Health Care
49
Michael BurkUbisoft Entertainment SA
N/A
LLB BECONRamsay Health Care
N/A
Michael QuartieriDave Busters Entertainment
55
John ParkesUbisoft Entertainment SA
53
Craig McNallyRamsay Health Care
62
Tony WehnerDave Busters Entertainment
55
Bryan McCroryDave Busters Entertainment
N/A
Christopher MorrisDave Busters Entertainment
52
Colleen HarrisRamsay Health Care
54
Kah HongRamsay Health Care
50
Randall JonesDave Busters Entertainment
N/A
Darryl LewisHollywood Bowl Group
N/A
Doug MeagherRamsay Health Care
N/A
Adam NovickasUbisoft Entertainment SA
N/A
Kelly HibbinsRamsay Health Care
N/A
Yves GuillemotUbisoft Entertainment SA
63
JeanBenot RoquetteUbisoft Entertainment SA
N/A
Andrew WearneRamsay Health Care
N/A
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana. ZIMMER BIOMET operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 19000 people. Zimmer Biomet Holdings (ZIM) is traded on Frankfurt Exchange in Germany and employs 18,000 people.

Management Performance

Zimmer Biomet Holdings Leadership Team

Elected by the shareholders, the Zimmer Biomet's board of directors comprises two types of representatives: Zimmer Biomet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zimmer. The board's role is to monitor Zimmer Biomet's management team and ensure that shareholders' interests are well served. Zimmer Biomet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zimmer Biomet's outside directors are responsible for providing unbiased perspectives on the board's policies.
Chad Phipps, Gen VP
Ivan Tornos, Chief Officer
Sang Yi, Group Pacific
Paul Stellato, Controller VP
Keri Mattox, Chief Relations
Wilfred Zuilen, Middle Europe
Suketu Upadhyay, Ex CFO
Zeeshan Tariq, VP Officer
Bryan Hanson, Pres Chairman
Nitin MD, Technology Science

Zimmer Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zimmer Biomet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Zimmer Stock

When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.